Viatris Inc. (VTRS): Price and Financial Metrics
GET POWR RATINGS... FREE!
VTRS POWR Grades
- Value is the dimension where VTRS ranks best; there it ranks ahead of 99.58% of US stocks.
- VTRS's strongest trending metric is Quality; it's been moving up over the last 177 days.
- VTRS's current lowest rank is in the Momentum metric (where it is better than 7.21% of US stocks).
VTRS Stock Summary
- VTRS's went public 35.3 years ago, making it older than 91.49% of listed US stocks we're tracking.
- In terms of twelve month growth in earnings before interest and taxes, VIATRIS INC is reporting a growth rate of -12,176.6%; that's higher than merely 0.2% of US stocks.
- VIATRIS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 34.55%, greater than the shareholder yield of 94.62% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to VIATRIS INC are OPK, LUNA, GNSS, BZFD, and CSPI.
- VTRS's SEC filings can be seen here. And to visit VIATRIS INC's official web site, go to www.viatris.com.
VTRS Valuation Summary
- In comparison to the median Healthcare stock, VTRS's price/earnings ratio is 76.72% lower, now standing at 5.4.
- Over the past 243 months, VTRS's EV/EBIT ratio has gone down 3.9.
Below are key valuation metrics over time for VTRS.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| VTRS | 2023-03-24 | 0.7 | 0.5 | 5.4 | 8.6 |
| VTRS | 2023-03-23 | 0.7 | 0.5 | 5.3 | 8.5 |
| VTRS | 2023-03-22 | 0.7 | 0.5 | 5.4 | 8.6 |
| VTRS | 2023-03-21 | 0.7 | 0.5 | 5.6 | 8.7 |
| VTRS | 2023-03-20 | 0.7 | 0.5 | 5.4 | 8.6 |
| VTRS | 2023-03-17 | 0.7 | 0.5 | 5.4 | 8.6 |
VTRS Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -11.78%.
- The 4 year cash and equivalents growth rate now stands at -20.92%.
- Its 4 year price growth rate is now at -55.64%.
The table below shows VTRS's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 16,728.3 | 3,333.1 | 803.6 |
| 2022-06-30 | 17,186.7 | 3,549.7 | 760.8 |
| 2022-03-31 | 17,647.7 | 3,306.6 | 167.7 |
| 2021-12-31 | 17,886.3 | 3,016.9 | -1,269.1 |
| 2021-09-30 | 17,168.2 | 2,530 | -1,921.1 |
| 2021-06-30 | 15,603.7 | 1,969.4 | -2,046.9 |
VTRS's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- VTRS has a Quality Grade of D, ranking ahead of 8.02% of graded US stocks.
- VTRS's asset turnover comes in at 0.298 -- ranking 155th of 682 Pharmaceutical Products stocks.
- CRIS, KDNY, and AGIO are the stocks whose asset turnover ratios are most correlated with VTRS.
The table below shows VTRS's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.298 | 0.277 | -0.030 |
| 2021-03-31 | 0.302 | 0.292 | -0.027 |
| 2020-12-31 | 0.312 | 0.318 | -0.011 |
| 2020-09-30 | 0.375 | 0.363 | 0.058 |
| 2020-06-30 | 0.375 | 0.356 | 0.052 |
| 2020-03-31 | 0.374 | 0.344 | 0.047 |
VTRS Price Target
For more insight on analysts targets of VTRS, see our VTRS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $20.21 | Average Broker Recommendation | 1.72 (Moderate Buy) |
VTRS Stock Price Chart Interactive Chart >
VTRS Price/Volume Stats
| Current price | $9.62 | 52-week high | $12.40 |
| Prev. close | $9.56 | 52-week low | $8.42 |
| Day low | $9.56 | Volume | 13,248,400 |
| Day high | $9.71 | Avg. volume | 9,401,795 |
| 50-day MA | $10.94 | Dividend yield | 5.02% |
| 200-day MA | $10.47 | Market Cap | 11.51B |
Viatris Inc. (VTRS) Company Bio
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania. The company was formed through the merger of Mylan and Upjohn, a division of Pfizer, on November 16, 2020. (Source:Wikipedia)
Latest VTRS News From Around the Web
Below are the latest news stories about VIATRIS INC that investors may wish to consider to help them evaluate VTRS as an investment opportunity.
Viatris asks for new bids for OTC business after initial offers disappoint - reportViatris (NASDAQ:VTRS) is asking for new offers for its European consumer-health assets after initial bids failed to meet its expectations. The company has asked potential buyers to resubmit their offers, according to a Bloomberg report, which cited people familiar. It's also decided to exclude erectile-dysfunction drug Viagra as part of the sale. Viatris (VTRS) was originally try to fetch €3 billion ($3.3 billion) for the sale and has been asking for offers for t... |
Viatris Wins Summary Judgment in New York Securities Class ActionViatris Inc. (NASDAQ: VTRS) announced that the U.S. District Court for the Southern District of New York has dismissed all claims against the Company in their entirety and granted its motion for summary judgment in the securities class action related to the Company's marketing, pricing, and classification of EpiPen, as well as alleged conduct concerning generic drug price fixing and market allocation. The decision addressed all pending claims against all defendants. |
Which Is the Better Dividend Stock: Viatris or Apple?Viatris (NASDAQ: VTRS) and Apple (NASDAQ: AAPL) are two dividend-paying stocks that don't have much in common, which can make them a bit difficult to compare as investments. Whereas Viatris makes generic medicines like Lipitor, Apple makes its own branded products like the iPhone. There are a few arguments for considering Viatris a better dividend stock than Apple, starting with the fact that the generic drug manufacturer will yield you a lot more in dividend income per dollar. |
Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention DrugViiV Healthcare and Medicines Patent Pool (MPP) have signed sublicence agreements with Aurobindo Pharma, Cipla Limited, and Viatris Inc (NASDAQ: VTRS) – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP). Aurobindo Pharma and Viatris will manufacture in India. Cipla Limited will manufacture in India and plans to manufacture in South Africa too. ViiV Healthcare is majority owned by GSK Plc (NYSE: GSK), with Pfize |
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate UpdateFinancial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025 PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis; $10 Million Milestone Linked to Approval Oral APX3330 Achieved Statistical Significance on a Potential Registration Endpoint for Diabetic Retinopathy in ZETA-1 Trial; End-of-Phase 2 FDA Meeting Planned FARMINGTON HILLS, Mich |
VTRS Price Returns
| 1-mo | -12.59% |
| 3-mo | -12.59% |
| 6-mo | 12.79% |
| 1-year | -7.09% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -12.59% |
| 2022 | -14.29% |
| 2021 | -26.12% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
VTRS Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...